PharmaNutra SpA (PHN) AI Stock Analysis

• Market Cap: €457.91M
• Dividend Yield: 2.11%
• Average Volume (3M): 4.55K
• Price to Earnings (P/E): 27.8
• Beta (1Y): 0.47
• Revenue Growth: 17.78%
• EPS Growth: 63.72%
• Country: IT
• Employees: 118
• Sector: Healthcare
• Sector Strength: 49
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.25
• Shares Outstanding: 9,680,977
• 10 Day Avg. Volume: 3,111
• 30 Day Avg. Volume: 4,550
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €53.00
• Price Target Upside: 11.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 73 Outperform
• Price Target: €53.00 ▲(11.58% Upside)

PharmaNutra SpA's overall stock score is driven by strong financial performance, characterized by solid profitability and robust cash flow. Technical analysis indicates neutral momentum, while the valuation suggests the stock is relatively high-valued. The absence of earnings call and corporate events data means these factors do not influence the score.

Positive Factors

Financial Performance

The company delivered a solid set of results, marked by double-digit top-line growth and continued its long-term investment cycle.

International Expansion

International operations remain the key growth driver, with PharmaNutra now present in 92 countries.

Market Position

Solid momentum was recorded across the main product families, with Sideral® confirming its market leadership in Italy.

Negative Factors

Margin Constraints

Management anticipates margin constraints in 2025-26 due to increased investments.

Profitability

Significant investments in new initiatives are expected to lead to a slight reduction in margins over the next two years.

Revenue Projections

The expected tangible results from PHN USA in H2 2025 are below expectations, affecting revenue projections.

PharmaNutra SpA Business Overview & Revenue Model

Company Description

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.

How the Company Makes Money

PharmaNutra generates revenue through the sale of its nutritional supplements and medical devices to both consumers and healthcare professionals. The company's revenue model is primarily driven by direct sales, partnerships with pharmacies, and collaborations with healthcare providers. Key revenue streams include the distribution of its proprietary formulations in domestic and international markets, where it leverages its research and development capabilities to innovate and expand its product line. Additionally, PharmaNutra benefits from strategic partnerships with other health-focused organizations that enhance its market reach and credibility, contributing to its financial performance.

PharmaNutra SpA Financial Statement Overview

Summary

PharmaNutra SpA demonstrates strong financial performance with consistent revenue growth and solid profitability metrics, including a gross profit margin of 66.8% and a net profit margin of 13.8%. The balance sheet is sound with moderate leverage and a healthy ROE of 25.5%. Cash flow is robust with a significant free cash flow growth rate of 27.3%. Minor areas for improvement include optimizing the gross profit margin and managing liabilities.

Income Statement

PharmaNutra SpA demonstrates strong financial performance with consistent revenue growth over the past years. The TTM data shows a gross profit margin of approximately 66.8% and a net profit margin of 13.8%, which are indicative of solid profitability. The EBIT margin is also robust at 22.9%, complemented by an EBITDA margin of 27.2%. These metrics suggest efficient cost management and operational effectiveness. However, the slight decline in gross profit from the previous period signals a potential area for improvement.

Balance Sheet

The company's balance sheet reflects a sound financial structure with a debt-to-equity ratio of 0.37, indicating moderate leverage. The equity ratio stands at 52.3%, showing a strong reliance on equity financing. Return on equity (ROE) is healthy at 25.5%, suggesting effective utilization of shareholder capital. However, the increase in total liabilities over time warrants cautious monitoring to ensure continued financial stability.

Cash Flow

PharmaNutra SpA's cash flow position is strong, with a significant free cash flow growth rate of 27.3% in the TTM period. The operating cash flow to net income ratio is 1.51, indicating robust cash generation from operations. The free cash flow to net income ratio is 1.26, highlighting good cash flow efficiency. Despite some fluctuations in capital expenditures, the company maintains a positive cash flow trajectory.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	119.20M	116.79M	101.03M	83.39M	68.58M	58.48M
Gross Profit	79.64M	82.79M	48.95M	30.17M	25.33M	21.30M
EBITDA	32.39M	32.01M	26.53M	24.61M	19.30M	15.10M
Net Income	16.41M	16.61M	12.83M	15.05M	13.77M	14.07M
Balance Sheet
Total Assets	123.33M	117.47M	112.44M	100.16M	71.36M	51.71M
Cash, Cash Equivalents and Short-Term Investments	30.76M	29.10M	25.12M	26.86M	33.94M	20.80M
Total Debt	24.05M	24.27M	28.02M	17.73M	6.35M	1.66M
Total Liabilities	58.86M	55.27M	58.04M	49.21M	26.27M	13.98M
Stockholders Equity	64.46M	62.16M	54.41M	50.95M	45.08M	37.73M
Cash Flow
Free Cash Flow	20.69M	16.25M	-1.16M	-8.69M	15.43M	10.46M
Operating Cash Flow	24.85M	20.50M	12.09M	14.47M	20.41M	11.79M
Investing Cash Flow	-2.42M	-2.21M	-14.70M	-23.71M	-5.54M	-598.00K
Financing Cash Flow	-13.97M	-21.59M	-516.00K	1.89M	-1.92M	-4.73M

PharmaNutra SpA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 47.50
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHN, the sentiment is Negative. The current price of 47.5 is below the 20-day moving average (MA) of 47.79, above the 50-day MA of 46.90, and below the 200-day MA of 50.30, indicating a neutral trend. The MACD of 0.31 indicates Positive momentum. The RSI at 48.91 is Neutral, neither overbought nor oversold. The STOCH value of 26.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHN.

PharmaNutra SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHN	73 Outperform	€457.91M	27.81		2.11%	17.78%	63.72%
Sector *	51 Neutral	$7.91B	-0.36	-41.70%	2.23%	23.45%	-1.86%
78Q	―	€687.21M	19.48	39.51%	―	―	―
COSMO	―	€18.10M	―		―	―	―
TALEA	―	€40.74M	―		―	―	―
ERFO	―	€13.44M	39.92		―	―	―
SVS	―	€43.81M	7.82		―	―	―